Authorization

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical

Quantum Genomics to receive up to $50 million in upfront and milestone payments plus double-digit royalties on sales
Qilu Pharmaceutical to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greater China region, including Hong Kong and MacaoPARIS and NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- QuantumA Genomics(EuronextA Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical to develop and commercialize firibastat in Greater China region, Hong Kong and Macao. After its first partnership in Asia, this new agreement is the second step of Quantum Genomicsa?? partnering strategy in Asia.Under the terms of the agreement, Qilu Pharmaceutical will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Geater China region including Hong Kong and Macao. Additionally, Qilu Pharmaceutical plans to join the globalA  study of difficult to treat/resistant hypertension in China.Quantum Genomics will receive upfront and milestone payments amounting up to $50 million, plus double-digit royalties on sales.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2020    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
28293031